Effectiveness of Osteoporosis Drug in Postmenopausal Women with Spinal Compression Fracture: Combined Consecutive Therapy of Teriparatide and Raloxifene versus Bisphosphonate Single

다국어 초록 (Multilingual Abstract)

Objective: Bisphosphonate, a typical bone resorption inhibitor, is an important first-line drug for treating osteoporosis. Recent studies show a novel paradigm in stimulating bone formation. Teriparatide, which is composed of recombinant human parathyroid hormone, stimulates osteoblasts and induces bone regeneration. Bone mineral density (BMD) that was used before and after the treatment with anti-osteoporosis drug was compared for the effectiveness in therapy between a combination of teriparatide and selective estrogen receptor modulator (SERM), and bisphosphonate.
Methods: We retrospectively reviewed the outcomes of 85 postmenopausal women who were concurrently diagnosed with osteoporosis and spinal compression fracture between November 2008 and January 2015. The targeted group were treated with teriparatide and SERM (TS group, n=26) and bisphosphonate (B group, n=59).
Results: In both groups, BMD of femur neck was not improved after the medication. In the TS group, on the other hand the BMD and T-score of lumbar spine has significantly improved. BMD ratio of lumbar spine was prominently higher than those of TS group.
Conclusion: The combination therapy of teriparatide and SERM was very effective in treating the lumbar spine, compared to that of bisphosphonate. Although the period of teriparatide treatment has been relatively short, the preventive effects of compression fracture were considerable. Thus, combination therapy of teriparatide and SERM is highly recommended for patients who are concerned with spinal compression fracture from osteoporosis.

참고문헌 (Reference)

1 Collinge C, "Use of teriparatide in osteoporotic fracture patients" 47 (47): S36-S38, 2016

2 Marcus R, "The skeletal response to teriparatide is largely independent of age, initial bone mineral density, and prevalent vertebral fractures in postmenopausal women with osteoporosis" 18 : 18-23, 2003

3 Chiang CY, "Teriparatide improves bone quality and healing of atypical femoral fractures associated with bisphosphonate therapy" 52 : 360-365, 2013

4 Lindsay R, "Sustained vertebral fracture risk reduction after withdrawal of teriparatide in postmenopausal women with osteoporosis" 164 : 2024-2030, 2004

5 Obermayer-Pietsch BM, "Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment" 23 : 1591-1600, 2008

6 Neer RM, "Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis" 344 : 1434-1441, 2001

7 Chen P, "Early changes in biochemical markers of bone formation predict BMD response to teriparatide in postmenopausal women with osteoporosis" 20 : 962-970, 2005

8 Niimi R, "Determinants associated with bone mineral density increase in response to daily teriparatide treatment in patients with osteoporosis" 66 : 26-30, 2014

9 Senn C, "Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study" 25 : 1945-1951, 2014

10 Pyung Goo Cho, "An effect comparison of teriparatide and bisphosphonate on posterior lumbar interbody fusion in patients with osteoporosis: a prospective cohort study and preliminary data" Springer Nature 2015